# OnCo record nct06256328 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06256328/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06256328", "NCT06256328" ;
  schema:name "A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)"@en ;
  schema:description "A phase 2 trial of Oxaliplatin, Capecitabine and Nivolumab in gastric & gastro-oesophageal junction cancer, run by Ono Pharmaceutical Co., Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06256328/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06256328> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-01-10" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/deciphera/> .